
1910 Genetics Inc Profile last edited on: 10/7/22
CAGE: 893V4
UEI: MGASA78GBGP3
Business Identifier: Utilizing AI to accelerate design of small molecule and protein therapeutics Is this YOUR Company?
Ensure accuracy and completeness of YOUR Company Profile by completing the brief Survey Instrument attached
Do you know about this Awardees?
Let us encourage you to provide any data which would enhance the completeness of this firm's profile.
Location Information
Location: Single
Congr. District: 08
County: Suffolk
Congr. District: 08
County: Suffolk
Public Profile
1910 Genetics is a biotechnology company integrating AI, computation, and biological automation to improve drug development: the design of small molecule and protein therapeutics. The firm is structured around decreasing the time and cost factor in drug development while also improving the success rate of achieving effective drugs: innovative medicines needed by patients. Currently, two drug discovery engines are in use enabling the design both of small molecule and of protein therapeutics not, so far, yet utilized in AI drug discovery space. Current focus of applying the firm's novel drug discovery approach involves several areas of investigation: neuroscience, infectious disease, immunology and oncology. With two drug discovery engines - ELVIS⢠and ROSALYND⢠- enabling the design of both small molecule and protein therapeutics -- an unmatched capability in the AI drug discovery space - the firm's therapeutic "area-agnostic, end-to-end technology" powers the full length of early drug discovery - from novel hit discovery to hit to lead, and lead optimization. At this point, the firm's technology andapproach to drug discovery address several areas including, but not limited to, neuroscience, infectious disease, immunology and oncolo
Extent of SBIR involvement
Synopsis: Awardee Business Condition
Employee Range
25-49Revenue Range
2.5M-5MVC funded?
YesPublic/Private
Privately HeldStock Info
----IP Holdings
N/AAwards Distribution by Agency
Most Recent SBIR Projects
Year | Phase | Agency | Total Amount | |
---|---|---|---|---|
2021 | 1 | NIH | $546,376 | |
Project Title: Development of selective calpain-1 inhibitors for chronic pain |
Key People / Management
Jennifer O Nwankwo -- Founder & CEO
Jennifer Bordeau -- Associate Director of Business Operations & Finance
Shannon Cosgrove -- Research Scientist
Austin Day -- AI Research Scientist III
Ken Fang -- Medicinal Chemistry Consultant
Brandon Moore -- Head of AI Research & ML Engineering
Anthony Navarro Sr -- Manager, Laboratory Operations, Compound Management, and Automation
Seun Olorunwunmi -- Software Engineer
Aesha Upadhyay -- Research Associate
Jennifer Bordeau -- Associate Director of Business Operations & Finance
Shannon Cosgrove -- Research Scientist
Austin Day -- AI Research Scientist III
Ken Fang -- Medicinal Chemistry Consultant
Brandon Moore -- Head of AI Research & ML Engineering
Anthony Navarro Sr -- Manager, Laboratory Operations, Compound Management, and Automation
Seun Olorunwunmi -- Software Engineer
Aesha Upadhyay -- Research Associate
Company News
There are no news available.